Therefore, this study is aimed to evaluate the cost-effectiveness of carboplatin-gemcitabine (CG) chemotherapy compared with erlotinib monotherapy as a first-line therapy for patients with EGFR mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.